1Milosavjevic D,Griglio S,Le Naour G,et al.Preferential reductionof very low density lipoprotein-1 particle number by fenofibrate intype II B hyperlipidemia;Consequences for lipid accumulation inhuman monoeyte derived macrophages[J].Atherosclerosis,2001,155(1):251.
9Bakris GL, Tarka EA, Waterhouse B,et al. Cardiovascular risk factors in hypertension:Rationale and design of studies to investigate the effects of controlled - release carvedilol on regression of left ventricular hypertrophy and lipid profile [J]. Am J Cardiol, 2006. 98(7A): 46L- 52L.
10Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial. Multiple risk factor intervention trial research group[J]. Arch Intern Med,1992,152(7):1490 - 1500.
7Nicholls SJ,Brandrup-Wognsen G,Palmer M,et al.Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids(from VOYAGER)[J].Am J Cardiol,2010,105(1):69-76.
8Yang J,Luo W,Chen L,et al.Metabolism of fenofibrate in beagle dogs:new metabolites identified and metabolic pathways revealed[J].Pharmazie,2013,68(6):414-420.
9SHAH PK. Plaque disruption and thrombosis: potential role of in-flammation and infection[J]. Cardiol Rev, 2000, 8(1): 31-39.
10MAX N, SUKHOVA GK, COLLINS T, et al. PPAR alpha acti- vators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells[J]. Circulation, 1999, 99 (24): 3125-3131.
